Nature: Influenza and SARS‑CoV‑2 can awaken dormant breast cancer cells and trigger lung metastasis
Posted inClinical Updates Infectious Diseases news Oncology Specialties

Nature: Influenza and SARS‑CoV‑2 can awaken dormant breast cancer cells and trigger lung metastasis

A Nature paper shows influenza and SARS‑CoV‑2 lung infections can reactivate dormant disseminated breast cancer cells (DCCs) via IL‑6 and CD4+ T‑cell–mediated mechanisms, with concordant human data linking SARS‑CoV‑2 infection to higher cancer‑related mortality and pulmonary metastasis risk.
Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us
Posted inClinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us

Recent randomized and mechanistic studies provide a nuanced view: metformin shows plausible anti‑aging mechanisms and microbiome‑linked cognitive associations, but randomized trials report no clear anti‑cancer or anti‑senescence effects in humans to date.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inCardiology Clinical Updates news Specialties

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.